ProQR Therapeutics NV

PRQR72

Penny Stock

$1.80arrow_drop_down1.63%-$0.03

Penny Stock

PRQR72

$1.80

arrow_drop_down1.63%-$0.03

Penny Stock

Performance History

Key Stats
Open	$1.81
Prev. Close	$1.82
EPS	-0.30
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$149.47M
PE Ratio	-

	LOW	HIGH
Day Range	1.70	1.85
52 Week Range	1.11	3.29

Ratios







EPS	-0.30

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About ProQR Therapeutics NV (PRQR)

ProQR Therapeutics NV (NASDAQ: PRQR) is a biopharmaceutical company focused on developing RNA-based therapeutics for the treatment of genetic diseases. The company's pipeline includes potential treatments for a range of rare diseases, including cystic fibrosis, Leber's congenital amaurosis, and Usher syndrome. ProQR's approach involves the use of antisense oligonucleotides, which are designed to target specific RNA sequences and correct the underlying genetic defect. By targeting the RNA, ProQR aims to address the root cause of the disease rather than just treating the symptoms.

One of ProQR's lead product candidates is QR-010, which is being developed for the treatment of cystic fibrosis. Cystic fibrosis is a genetic disease that affects the respiratory and digestive systems and can lead to severe health complications. QR-010 is designed to restore functional CFTR protein production in patients with the most common mutation causing cystic fibrosis. The treatment is being evaluated in a Phase 2b clinical trial, with results expected in the near future.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Daniel Anton de Boer
Headquarters: Leiden
Employees: 130
Exchange: NASDAQ

Keep an eye on ProQR Therapeutics NV

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is ProQR Therapeutics NV's (PRQR) price per share?

The current price per share for ProQR Therapeutics NV (PRQR) is $1.8. The stock has seen a price change of -$0.03 recently, indicating a -1.64% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for ProQR Therapeutics NV (PRQR)?

For ProQR Therapeutics NV (PRQR), the 52-week high is $3.29, which is 82.78% from the current price. The 52-week low is $1.11, the current price is 62.16% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is ProQR Therapeutics NV (PRQR) a growth stock?

ProQR Therapeutics NV (PRQR) has shown an average price growth of 0.41% over the past three years. It has received a score of 87 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ProQR Therapeutics NV as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is ProQR Therapeutics NV (PRQR) stock price performance year to date (YTD)?

As of the latest data, ProQR Therapeutics NV (PRQR) has a year-to-date price change of -13.25%. Over the past month, the stock has experienced a price change of -13.46%. Over the last three months, the change has been 5.88%. Over the past six months, the figure is -27.13%. Looking at a longer horizon, the five-year price change stands at -74.75%.

help

Is ProQR Therapeutics NV (PRQR) a profitable company?

ProQR Therapeutics NV (PRQR) has a net income of -$27.54M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -55.72% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $6.38M, with a revenue growth rate of 58.05%, providing insight into the company's sales performance and growth. The gross profit is $6.38M. Operating income is noted at -$34.16M. Furthermore, the EBITDA is -$30.38M.

help

What is the market capitalization of ProQR Therapeutics NV (PRQR)?

ProQR Therapeutics NV (PRQR) has a market capitalization of $149.47M. The average daily trading volume is 72.84K, indicating the stock's liquidity and investor engagement.